Brookfield and MidOcean make an $18bn Origin Energy bid; Shareholders & the board like it

Nick Sundich Nick Sundich, November 10, 2022

Brookfield and Midocean have made another Origin Energy bid and this time it might be a case of third time lucky. Two earlier bids were met with the cold shoulder but after twice increasing the price, Origin Energy told shareholders it would back the bid if it became a formal, binding offer.  

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

The third Origin Energy bid this year

Since August, Origin Energy and its suitors have negotiated behind closed doors. The first bid was at $7.95 per share (inclusive of Origin’s H2 FY22 dividend) and the second was at $8.70-$8.90 per share.

This morning, the third Origin Energy bid was made public, coming in at $9 a share which values the company at $18.4bn. Origin shares rose by 34% to $7.84 at the market open, but falling short of the indicated offer.

 

origin energy bid

 

The offer looks like it will go ahead

This Origin Energy bid is a 55% premium to yesterday’s closing price and unsurprisingly, Origin’s board told shareholders it would recommend shareholders accept the offer if it became a binding offer and in absence of a superior proposal. 

If the Origin Energy bid is accepted goes ahead, the company would be split in two with MidOcean taking Australia Pacific LNG and Brookfield taking Origin’s core electricity and gas retailing and supply business. The share price rise this morning indicates that shareholders are optimistic that the deal will be completed. 

 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

Blog Categories

Get the Latest Insider Trades on ASX!

Recent Posts

These 2 ASX Healthcare Stocks Are Quietly Cashing In on the AI Revolution

ASX Healthcare Stocks Benefiting From AI Artificial intelligence is reshaping healthcare faster than most investors realise. Hospital imaging systems, pathology…

Which ASX Uranium Stocks Benefit Most From the Iran War and the Hormuz Oil Crisis?

ASX Uranium Stocks to Watch This Week Brent crude is sitting just above US$111 a barrel as of this morning,…

Telix pharmaceuticals (ASX: TLX) A$230m Quarter Puts Guidance Back In Play

Is Telix in Turnaround Mode or Dead-Cat Bounce? The question investors are now asking about Telix pharmaceuticals is whether the…